Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptors (EGFR) (EGFR-TKIs) significantly prolong the survival of lung adenocarcinoma patients with sensitizing EGFR mutations. Unfortunately, 10–30% patients do not show objective responses to EGFR-TKIs, and undergo rapid disease progression. We found that miR-608 and miR-4513 polymorphisms are independent biomarkers to predict lung adenocarcinoma patients’ survival after EGFR-TKI treatment. These miRNAs and polymorphisms provide clinical potential in patient-tailored treatment decision-making.
- Nasha Zhang
- Yankang Li
- Ming Yang
